Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease

P. Szabolcs, M. Reese, K. B. Yancey, R. P. Hall, J. Kurtzberg

Research output: Contribution to journalArticlepeer-review

65 Scopus citations

Abstract

In this case report we describe a novel treatment with two chimeric monoclonal antibodies (MoAb) targeting the autoimmune B cell clone responsible for bullous pemphigoid (BP) as a manifestation of steroid refractory chronic graft-versus-host disease (GVHD) that developed after unrelated cord blood transplantation. Monitoring the BP-specific circulating antibodies and CD25-expressing activated T lymphocyte subset led us to combine anti-CD20 (Rituximab) mediated B cell ablation with anti-CD25 (Daclizumab) therapy to block CD4+ T cell help. Complete clinical and serologic response was achieved within 4 weeks of initiation of therapy allowing global immunosuppression to be dramatically reduced.

Original languageEnglish (US)
Pages (from-to)327-329
Number of pages3
JournalBone Marrow Transplantation
Volume30
Issue number5
DOIs
StatePublished - Sep 2002

Keywords

  • Bullous pemphigoid
  • Daclizumab
  • GVHD
  • Rituximab
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease'. Together they form a unique fingerprint.

Cite this